You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)avapritinib針對晚期GIST的I/II期橋接註冊性試驗完成中國首例受試者給藥
阿思達克 08-25 23:34

基石藥業-B(02616.HK)公布,由基石藥業合作夥伴 Blueprint Medicine

Corporation(納斯達克股份代號:BPMC)(「Blueprint」)開發的avapritinib 的I/II期橋接註冊性試驗實現中國首例受試者給藥。這是一項中國單獨的橋接註冊性研究,包括I期劑量遞增和II期劑量擴展試驗,目的是評估avapritinib在不可手術切除或轉移性胃腸道間質瘤(「GIST」)患者中的安全性、藥代動力學和療效。該試驗將包括PDGFRA D842V基因驅動的GIST和二線、三線及以上的GIST患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account